Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

Casarini IA, Kowalski DM, Caglevic C, Karaca Yayla B, Sumbul AT, Yañez Weber P, Yanzi Castilla AN, Bylicki O, Takagi T, McQuarrie K, Saraf S, Arunachalam A, Bhagwati N, Cohen G

Open source

DOI: 10.1200/op-25-01248
Published: 2026 Jun 3
Container: JCO oncology practice
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/op-25-01248,
  title = {Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.},
  author = {Casarini IA and Kowalski DM and Caglevic C and Karaca Yayla B and Sumbul AT and Yañez Weber P and Yanzi Castilla AN and Bylicki O and Takagi T and McQuarrie K and Saraf S and Arunachalam A and Bhagwati N and Cohen G},
  year = {2026},
  journal = {JCO oncology practice},
  doi = {10.1200/op-25-01248},
  url = {https://doi.org/10.1200/op-25-01248}
}

RIS

TY  - JOUR
TI  - Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.
AU  - Casarini IA
AU  - Kowalski DM
AU  - Caglevic C
AU  - Karaca Yayla B
AU  - Sumbul AT
AU  - Yañez Weber P
AU  - Yanzi Castilla AN
AU  - Bylicki O
AU  - Takagi T
AU  - McQuarrie K
AU  - Saraf S
AU  - Arunachalam A
AU  - Bhagwati N
AU  - Cohen G
PY  - 2026
JO  - JCO oncology practice
DO  - 10.1200/op-25-01248
UR  - https://doi.org/10.1200/op-25-01248
ER  -

APA

IA, C., DM, K., C, C., B, K. Y., AT, S., P, Y. W., AN, Y. C., O, B., T, T., K, M., S, S., A, A., N, B., & G, C. (2026). Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.. JCO oncology practice. https://doi.org/10.1200/op-25-01248

Source records

pubmed · retrieved 2026-09-25T20:51:56.296Z